TY - JOUR
T1 - Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood
T2 - A children's oncology group phase 2 study
AU - Bradley, Kristin A.
AU - Zhou, Tianni
AU - McNall-Knapp, Rene Y.
AU - Jakacki, Regina I.
AU - Levy, Adam S.
AU - Vezina, Gilbert
AU - Pollack, Ian F.
N1 - Funding Information:
This research was supported by Children's Oncology Group grant CA 98543 from the National Cancer Institute, National Institutes of Health .
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Purpose: To evaluate the effects on 1-year event-free survival (EFS) and overall survival (OS) of combining motexafin and gadolinium (MGd), a potent radiosensitizer, with daily fractionated radiation therapy in children with newly diagnosed intrinsic pontine gliomas. Methods and Materials: Patients with newly diagnosed intrinsic pontine glioma were treated with MGd daily for 5 consecutive days each week, for a total of 30 doses. Patients received a 5- to 10-min intravenous bolus of MGd, 4.4 mg/kg/day, given 2 to 5 h prior to standard dose irradiation. Radiation therapy was administered at a daily dose of 1.8 Gy for 30 treatments over 6 weeks. The total dose was 54 Gy. Results: Sixty eligible children received MGd daily, concurrent with 6 weeks of radiation therapy. The estimated 1-year EFS was 18% ± 5%, and the estimated 1-year OS was 53% ± 6.5%. The most common grade 3 to 4 toxicities were lymphopenia, transient elevation of liver transaminases, and hypertension. Conclusions: Compared to historical controls, the addition of MGd to a standard 6-week course of radiation did not improve the survival of pediatric patients with newly diagnosed intrinsic pontine gliomas.
AB - Purpose: To evaluate the effects on 1-year event-free survival (EFS) and overall survival (OS) of combining motexafin and gadolinium (MGd), a potent radiosensitizer, with daily fractionated radiation therapy in children with newly diagnosed intrinsic pontine gliomas. Methods and Materials: Patients with newly diagnosed intrinsic pontine glioma were treated with MGd daily for 5 consecutive days each week, for a total of 30 doses. Patients received a 5- to 10-min intravenous bolus of MGd, 4.4 mg/kg/day, given 2 to 5 h prior to standard dose irradiation. Radiation therapy was administered at a daily dose of 1.8 Gy for 30 treatments over 6 weeks. The total dose was 54 Gy. Results: Sixty eligible children received MGd daily, concurrent with 6 weeks of radiation therapy. The estimated 1-year EFS was 18% ± 5%, and the estimated 1-year OS was 53% ± 6.5%. The most common grade 3 to 4 toxicities were lymphopenia, transient elevation of liver transaminases, and hypertension. Conclusions: Compared to historical controls, the addition of MGd to a standard 6-week course of radiation did not improve the survival of pediatric patients with newly diagnosed intrinsic pontine gliomas.
UR - http://www.scopus.com/inward/record.url?scp=84871373647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871373647&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2012.09.004
DO - 10.1016/j.ijrobp.2012.09.004
M3 - Article
C2 - 23092726
AN - SCOPUS:84871373647
SN - 0360-3016
VL - 85
SP - e55-e60
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 1
ER -